Hintergrund. Die gegensätzlichen Wirkungen des L-Arginin-NO-Stoffwechsels bei Nierenerkrankungen wurden nachgewiesen. Die vorliegende Studie untersucht die Haupt-Endstrecke dieses Stoffwechselweges, die NO-cGMP-Signaltransduktion, sowie die Wirkung des spezifischen sGC-Stimulators Bay 41-2272 auf Schädigungs-, Matrixexpansions- und Progressionsphase der Anti-Thy1-induzierten Nierenerkrankungen im Rattenmodell. Methoden. Die anti-Thy1-Antikörperinjektion in zwei Nieren- oder uninephrektomierten Ratten induzierte eine Sequenz der Schädigungs-, Matrixexpansions- und Progressionsphase. Die Effekte der Behandlung mit Bay 41-2272 (10 mg/kg Körpergewicht/Tag) wurden durch die Messungen von systolischem Blutdruck, Proteinurie, Nierenfunktion, glomerulärer und interstitieller Matrixakkumulation, TGF-beta1-, Fibronectin- und PAI-1-Expression, Makrophageninfiltration, alpha1sGC, beta1sGC, sowie basaler und NO-stimulierter renaler cGMP-Produktion ermittelt. Im chronischen Anti-Thy1 Modell wurden die Effekte von Bay 41-2272 mit dem reinen Vasodilator Hydralazin (15 mg/kg Körpergewicht/Tag) verglichen. Ergebnisse. Im Vergleich zu den Kontrollen sind die sGC mRNA Expression und Aktivität signifikant im Matrixexpansionsprotokoll erhört, während sie im Schädigungsprotokoll komplett vermindert sind; im Progressionsprotokoll ist die sGC-cGMP-Kaskade im Tubulointerstitium hochreguliert, während die Aktivität im Glomeruli erniedrigt ist. Im Gegensatz zur Hydralazin-therapie erhörte die Bay 41-2272-Behandlung die glomeruläre und die tubulointerstitielle NO-cGMP-Signaltransduktion. Dies führte zu deutlich verringerten Makrophageninfiltration, Matrixakkumulation sowie einer verbesserten Nierenfunktion. Schlussfolgerung. Die Expression und Aktivität der sGC sind auf Transkriptionsebene im Verlauf der Nierenfibrose hochreguliert und korrelieren eng mit den pathologischen Veränderungen in den einzelnen Krankheitsphasen. Pharmakologische sGC-Stimulation reduzierte die TGF-beta-Überexpression sowie die Matrixakkumulation und verlangsamte den fortschreitenden Verlauf zur tubulointerstitiellen Fibrose und eingeschränkten Nierenfunktion über teilweise blutdruckunabhängige Mechanismen, obwohl die Mesangialzelllyse infolge der verminderten sGC-Expression unbeeinflusst blieb. Die Ergebnisse zeigen, dass die NO-cGMP-Signaltransduktion ein wichtiger antifibrotischer Mechanismus bei Nierenfibrose ist. / Background Controversial effects of L-arginine-NO pathway have been shown on renal disease. The present study analyzes the main downstream of L-arginine-NO pathway, the NO-cGMP signaling in and the effect of the specific sGC stimulator Bay 41-2272 on the injury, matrix expansion and progression phases in the rat model of anti-thy1-induced renal disease. Methods The injection of anti-thy1 antibody into rats with two kidneys or nephrectomized rats caused a sequence of the injury, matrix expansion and progression phases. The effects of Bay 41-2272 (10 mg/kg body weight/d) treatment on systolic blood pressure, proteinuria, kidney function, glomerular and tubulointerstitial matrix protein accumulation, expression of TGF- beta1, fibronectin and PAI-1, macrophage infiltration, alpha1sGC and beta1sGC mRNA expression and basal and NO-stimulated renal cGMP production were determined. In the chronic anti-thy1 model, the effect of Bay 41-2272 was compared side-by-side to the sole vasodilator hydralazine (15 mg/kg body weight/d). Results Compared to controls, sGC mRNA expression and activity were markedly increased in the matrix expansion protocol, while they were almost completely disrupted in the injury protocol; in the progression protocol, sGC-cGMP cascade was up-regulated in the tubulointerstitium, while its activity was decreased in glomeruli. In contrast to hydralazine therapy, Bay 41-2272 treatment enhanced both glomerular and tubulointerstitial NO-cGMP signaling significantly, resulting in markedly reduced macrophage infiltration, matrix expression and accumulation as well as improved kidney function. Conclusion The expression and activity of sGC are highly regulated at the transcriptional level during the course of renal fibrosis, and correlate closely with the pathological changes from the injury over the matrix expansion toward the final progression phase. Further pharmacologic sGC stimulation reduced TGF-beta overexpression and extracellular matrix accumulation and limited the progressive course of this model towards tubulointerstitial fibrosis and impaired renal function at least in part in a blood pressure-independent manner, although it demonstrated no effects on mesangial cell lysis due to lack of the receptor sGC. The results suggest that NO-cGMP signaling represents an important anti-fibrotic pathway in renal fibrosis.

Endothelial cells (EC) are essential regulator of vascular homeostasis through the generation and release of various bioactive agents, including nitric oxide (NO). NO modulates several vascular functions such as vascular tone and permeability, through the stimulation of soluble guanylate cyclase (sGC) leading to the production of cGMP. Conversely, phosphodiesterases (PDEs) are enzymes metabolizing cyclic nucleotides (cGMP and cAMP) and are therefore major regulatory players for cGMP and cAMP signalling pathways. Although ECs are the main source of NO, little is known on the endothelial NO-cGMP signalling pathway and cellular outcomes. It was then hypothesized that a specific population of cGMP-phosphodiesterases allows ECs to stabilize cGMP levels despite the elevated production of NO. Expression of cGMP-phosphodiesterases was initially studied in resistance mesenteric arteries from mice. PDE5 and PDE6 were both found at mRNA and protein levels in native arteries but PDE6 is not found in cultured ECs. Interestingly, subcellular distributions of both enzymes were distinct. PDE5 appeared to be homogeneously distributed whilst PDE6 catalytic subunits (PDE6 and PDE6) showed a preferential staining in the perinuclear region. These results suggest that PDE6 might be involved in the regulation of cGMP microdomains. Based on these findings, a mathematical model was developed. Simulations of dynamic cGMP levels in ECs support the notion of cGMP microdomains dependent on PDE6 expression and localization. In the absence of PDE6, application of NO either as a single bolus or repetitive pulses led to a homogeneous increase in cGMP levels in ECs despite PDE5 homogeneous distribution. However, PDE6 subcellular targeting to the perinuclear membrane generated a cGMP-depleted perinuclear space. The findings from this study provide the first evidence of the expression and specific intracellular distribution of PDE6 in native endothelial cells that strongly support their involvement in the generation of cGMP microdomains / Les cellules endothéliales (CEs) participent au maintien de l’homéostasie vasculaire en générant et libérant de nombreux agents bioactifs, incluant l’oxyde nitrique (NO). Le NO module plusieurs fonctions vasculaires telles que le tonus et la perméabilité vasculaire via la stimulation de la guanylate cyclase soluble (GCs) provoquant la formation de GMPc. D’autre part, les phosphodiestérases (PDEs) sont des enzymes métabolisant les nucléotides cycliques (GMPc et AMPc) et participent donc à des étapes essentielles du contrôle des voies de signalisation du GMPc et de l’AMPc. Bien que les CEs soient la source principale de NO, la voie de signalisation NO-GMPc endothéliale et les répercussions fonctionnelles demeurent méconnues. Nous avons alors émis l’hypothèse qu’une population spécifique de PDEs ciblant le GMPc (PDEs-GMPc) permettrait aux CEs de maintenir des niveaux de GMPc faible malgré l’importante production de NO. L’expression des isoformes de PDEs-GMPc dans les artères mésentériques de souris fut initialement déterminée. PDE5 et PDE6 furent détectées tant sous la forme d’ARNm que de protéines dans les artères natives alors que PDE6 est absente de lignées de CEs en culture. La distribution intracellulaire des deux enzymes est distincte. Alors que PDE5 est distribué uniformément dans le cytoplasme des cellules endothéliales, les sousunités catalytiques de PDE6 ( et ) sont préférentiellement présentes dans la région périnucléaire. Ces résultats suggèrent que PDE6 puisse être impliqué dans le contrôle de microdomaines de GMPc. Des simulations effectuées à l’aide d’un modèle mathématique développé sur la base de ces données sont en accords avec la notion selon laquelle l’expression et la distribution subcellulaire de PDE6 sont responsables de microdomaines de GMPc dans l’endothélium. En absence de PDE6, l’ajout de NO sous forme de bolus unique ou répétée mène à une augmentation homogène de la concentration cytoplasmique en GMPc malgré la présence de PDE5. Toutefois, la présence de PDE6 à la membrane péri-nucléaire crée un espace péri-nucléaire pauvre en GMPc. Les résultats de cette étude forment les premières évidences de l’expression et de la distribution intracellulaire hétérogène de PDE6 dans les cellules endothéliales natives et suggèrent leur implication dans la génération de microdomaines.

O óxido nítrico (NO) é um mensageiro químico gerado pela atividade da enzima óxido nítrico sintase (NOS) a qual foi detectada em vários órgãos incluídos os do sistema reprodutor e parece estar envolvido na maturação oocitária. No entanto, há poucos estudos sobre o papel desse sistema em oócitos da espécie bovina. Sabe-se que o NO atua pela via da guanilato ciclase (GC) estimulando a produção do nucleotídeo GMPc, que por sua vez é capaz de influenciar nos níveis de outro nucleotídeo (AMPc) via fosfodiesterases (PDE). O AMPc é um importante elemento da via de sinalização do FSH nos complexos cumulus-oócitos e no controle da maturação oocitária. O objetivo do presente projeto foi investigar a influência do FSH na via do NOS/NO e seus componentes em oócitos bovinos maturados in vitro e o envolvimento das células do cumulus (CC) na via de sinalização. Para tanto, complexos cumulus-oócito (CCO) e oócitos desnudos (OD - maturados sem células do cumulus) foram maturados in vitro por 24h na presença ou ausência de FSH. As amostras foram avaliadas quanto a: 1) taxa da maturação nuclear; 2) níveis de produção de NO; 3) níveis de AMPc e GMPc; 4) abundância relativa de RNAm de NOS2, PDE5A, PDE6C, PKG1, PKG2, ADCY6, ADCY9, PDE3A e PKA1. O FSH, na concentração de 0,05UI/mL, estimulou positivamente a maturação nuclear em CCO e OD, com 80,6 e 89% de oócitos maturados, respectivamente. Quando comparados diretamente os grupos CCO e OD, o FSH não influenciou as taxas de maturação (71 e 71,3%, p>0,05), nem os níveis de produção de NO (12,8 e 7,4 µM/mL, p>0,05). Os níveis de GMPc em CCO aumentaram após 1 e 3 h de MIV na presença de FSH (266,3 e 187,2 pmol/pool com FSH e 240,5 e 168,5 pmol/pool sem FSH, respectivamente, p<0,05). Após 6 h os níveis de GMPc declinaram de forma mais acentuada no grupo sem FSH (46,3 e 106,9 pmol/pool, com e sem FSH, respectivamente, p<0,05). Os níveis de AMPc em CCO também foram mais elevados na presença de FSH à 1 e 3 h de MIV (7,60 e 7,81 pmol/pool, respectivamente) em comparação com CCO maturados sem FSH (0.30 e 0,76 pmol/pool, respectivamente, p<0,05). Após 6h, os níveis declinaram e foram similares para ambos os grupos (0,43 pmol/pool, p>0,05). Em relação à expressão dos genes selecionados, todos foram detectados nos oócitos (CCO e OD), porém, em células do cumulus, foram detectados apenas PDE5A, ADCY6, ADCY9 e PKA1. Quando observados os resultados do grupo CCO, apenas os genes PKG1, ADCY6 e PDE3A sofreram influência do FSH (p<0,05), apresentando um aumento destes transcritos. No grupo OD, apenas o gene PKG1 sofreu influência do FSH, também apresentando um aumento destes transcritos (p<0,05). Em células do cumulus, os genes ADCY6 e ADCY9 sofreram influência do FSH, sendo que para a ADCY6 provocou um aumentos destes transcritos, e para a ADCY9 provocou uma queda dos mesmos (p<0,05). Em conclusão, o FSH pode exercer influência positiva na maturação nuclear de oócitos bovinos, agindo sobre os níveis de GMPc e AMPc, mas não sobre o NO. O FSH pode influenciar a expressão gênica em oócitos e em células do cumulus de bovinos. / Nitric oxide (NO) is a chemical messenger generated by the nitric oxide synthase (NOS) enzyme, which was detected in several organs including the reproductive system and appears too involved in oocyte maturation. However, there are few studies on the role of this system in bovine oocytes. NO is known to act via guanylate cyclase (GC) stimulating the production of the nucleotide cGMP, which in turn is capable of influencing the levels of another nucleotide, cAMP via phosphodiesterases (PDE). cAMP is an important factor in FSH signaling in cumulus-oocyte complexes (COC) for the control of maturation. The aim of the present work was to investigate the influence of FSH on the NOS/NO pathway and its components in bovine oocytes matured in vitro and the involvement of cumulus cells (CC) in the signaling pathway. COC and denuded oocytes (DO - matured without cumulus cells) were matured in vitro for 24 h with or without FSH. Samples were assessed for: 1) maturation rate; 2) levels of NO production; 3) levels of cGMP and cAMP; 4) relative abundance for mRNA of NOS2, PDE5A, PDE6C, PKG1, PKG2, ADCY6, ADCY9, PDE3A and PKA1. FSH positively stimulated oocyte maturation at 0.05UI/mL concentration for both COC and OD (80.6 and 89% maturation rates, respectively). When COC and OD were compared directly, FSH did not affect maturation rates (71 and 71.3%, p>0.05) nor NO production levels (12,8 and 7,4 µM/mL), p>0.05). cGMP levels increased after 1 and 3 h in vitro maturation (IVM) with FSH (266.3 and 187.2 pmol/pool with FSH and 240.5 and 168.5 pmol/pool without FSH, respectively, p<0.05). After 6 h IVM, cGMP levels in COC declined more in the group cultured with FSH (46.3 and 106.9 pmol/pool, with and without FSH, respectively, p<0.05). cAMP levels in COC were also increased in the presence of FSH at 1 and 3 h IVM (7.60 and 7.81 pmol/pool, respectively) in comparison to COC cultured without the hormone (0.30 and 0.76 pmol/pool, respectively, p<0.05). After 6 h, the levels declined and were similar for both groups (0.43 and 0.02 pmol/pool, p>0.05). Regarding mRNA expression for the selected genes, all of them were detected in oocytes, but only four of them were detected in cumulus cells: PDE5A, ADCY6, ADCY9 and PKA1. For COC only PKG1, ADCY6 and PDE3A were influenced by FSH (p<0.05), with an increase in transcript relative abundance, For DO, only PKG1 was influenced by FSH and also showed an increase in these transcripts (p<0.05). In cumulus cells, ADCY6 and ADCY9 were affected by FSH, with an increase for ADCY6 and a decrease in ADCY9 transcripts (p<0.05). In conclusion, FSH may positively influence nuclear maturation, acting on cGMP and cAMP levels, but not on NO. FSH may also influence gene expression in bovine oocytes and cumulus cells.

O gás composto monóxido de carbono (CO), está envolvido na modulação de diferentes funções orgânicas, tais como a regulação cardiovascular, a temperatura corporal e a nocicepção. A participação do CO nos processos fisiológicos ocorre por meio da atividade da enzima heme-oxigenase (HO), e seu produto CO, o qual por sua vez aumenta a produção de guanosina monofosfato ciclíco intracelular (GMPc). De particular interesse, o locus coeruleus possui elevada expressão da enzima HO-2 sugerindo o envolvimento do gasotransmissor CO na modulação das funções executadas por esta estrutura encefálica. O objetivo deste trabalho foi avaliar o envolvimento da via HO-CO do LC na modulação da ansiedade, avaliada pelo teste de labirinto em cruz elevado e teste claro-escuro; nocicepção aguda, avaliada pelo teste de retirada de cauda e a nocicepção inflamatória, avaliada pelo teste de formalina em ratos. Para atingir estes objetivos, ratos (± 250grs; Wistar) foram anestesiados (ketamina 75 mg/kg e xilasina 10 mg/kg i.m.) e submetidos à cirurgia estereotáxica para implante unilateral de cânulas-guias direcionadas para o LC, e para o ventrículo lateral. Após o período de recuperação, os ratos foram divididos em distintos grupos experimentais para administração intra-LC do ZnDPBG (inibidor inespecífico da enzima HO, nas doses 5,50 ou 200 nmol/0,1 µl) ou seu veículo, Na2CO3 (50 mmol/0,1 µl); do Heme-lisinato (150, 300 ou 600 nmol/0,1 µl) ou seu veículo, L-lisina (14,2 µmol/0,1 µl); do ODQ i.c.v. (inibidor específico da enzima guanilase ciclase solúvel, 1,3 nmol/1,0 µl) ou seu veículo (DMSO 1%, 1,0 µl) e após 15 min o Heme-lisinato (600 nmol/0,1 µl) ou seu veículo (L-lisina, 14,2 µmol/0,1 µl), intra-LC. Após o tempo de 15 min, os ratos foram avaliados no teste de LCE ou no TCE por 5 minutos, no teste de retirada de cauda por 120 minutos e no teste de formalina intra-podal por 45 minutos. Os resultados obtidos mostram que o aumento da produção do neuromodulador gasoso CO no LC, pela ativação da via HO-CO-GMPc com Heme-lisinato, promove efeito ansiolítico avaliado no teste do LCE e no TCE, evidenciado pelo aumento do tempo de permanência e pelo aumento do número de entradas nos braços abertos do LCE, e pelo aumento tempo de permanência no compartimento claro do TCE. Este efeito ansiolítico é dependente da atividade de GMPc intracelular, desde que o tratamento i.c.v. com inibidor específico da enzima GCs bloqueou os efeitos do Heme-lisinato no LCE e no TCE. Ainda, a ativação da via HO-CO-GMPc por meio da administração intra-LC do Heme-lisinato promoveu efeito antinociceptivo frente estímulo térmico agudo (teste de retirada de cauda em ratos), sendo este efeito dependente da atividade do GMPc, desde que o pré-tratamento com o inibidor da enzima guanilase ciclase solúvel, ODQ, bloqueou o aumento do IARC. O bloqueio da via HO-CO promove efeito hipernociceptivo em modelo de dor inflamatória, desde que o tratamento intra-LC com inibidor inespecífico da HO, ZnDPBG aumenta o número de sacudidas no teste de formalina intra-podal. Assim, este estudo é pioneiro em demonstrar que o neuromodulador CO do LC modula a ansiedade e a nocicepção aguda térmica e inflamatória. / The gas composed carbon monoxide (CO) is involved in the modulation of various physiological functions such as cardiovascular regulation, nociception and body temperature. CO participation in physiological processes occurs through the activity of the enzyme heme oxygenase (HO), and its product CO, which in turn increases the production of intracellular cyclic guanosine monophosphate (cGMP). In particular interest, the locus coeruleus (LC) has a high HO-2 enzyme expression suggesting the involvement of CO in the modulation of the functions performed by this brain structure. The aim of this study was to evaluate the involvement of HO-CO pathway of LC in modulating anxiety, assessed by elevated plus maze test and light-dark box test. Additionally, acute nociception, as assessed by the tail flick test and inflammatory nociception, as assessed by formalin test in rats were analyzed after HO-CO pathway activation. Rats (±250 grs; Wistar) were anesthetized (ketamine 75 mg/kg and xylazine 10 mg/kg im) and underwent stereotactic surgery for cannulas guides unilateral implantation directed to the LC, and to the lateral ventricle. After the recovery period, rats were divided into distinct experimental groups for intra-LC ZnDPBG (nonspecific enzyme inhibitor HO doses 5, 50 or 200 nmol/0.l µl) or its vehicle, Na2CO3 (50 mmol/0.l µl); Heme-lysinate (150, 300 or 600 nmol/0.l µl) or its vehicle, L-lysine (14.2 nmol/0.1 µl), the ODQ i.c.v. (specific inhibitor of the enzyme guanilase soluble cyclase, 1.3 nmol/1.0 µl) or its vehicle (1% DMSO, 1.0 µl) and after 15 min the Heme-lysinate (600 nmol/0.1 µl), or its vehicle (L-lysine, 14.2 mmol/0.1 µl), intra-LC. After time 15 min, rats were evaluated in the EPM test or LDB for 5 minutes and in the tail flick test for 120 minutes and in the formalin test for 45 minutes. The results show that CO increased production in LC, by HO-CO-cGMP pathway activation, promotes anxiolytic effect evaluated in the EPM test and LDB. The anxiolytic effect is dependent on the activity of intracellular cGMP, since treatment i.c.v. with enzyme sGC inhibitor blocked the effects of Heme-lysinate. Moreover, the activation of the HO-CO-cGMP pathway into the LC promoted antinociceptive effect in the tail flick test, this effect being dependent on the activity of cGMP, since pre-treatment with the guanilase cyclase soluble inhibitor, ODQ, blocked the increase in analgesic index. Furthermore, the block of the HO-CO pathway intra-LC promoted hypernociception in a model of inflammatory pain, since treatment with nonspecific inhibitor HO, ZnDPBG, increases the nociceptive behavior in the formalin test. Thus, this study is the first to demonstrate that the CO neuromodulator into LC modulates anxiety and acute thermal and inflammatory nociception.

L'AMP cyclique (AMPc) et le GMP cyclique (GMPc) sont des seconds messagers essentiels pour la régulation de la fonction cardiaque. Leurs niveaux sont régulés par l’adénylate cyclase et la guanylate cyclase, respectivement, et par les phosphodiestérases (PDEs). Cependant, une telle régulation est altérée dans l'insuffisance cardiaque (IC). En effet, la diminution de la signalisation de l’AMPc et l’augmentation de celle du GMPc est caractéristique des cœurs défaillants.Parmi la superfamille des PDEs, la PDE2 a la particularité d'être stimulée par le GMPc, conduisant ainsi à une augmentation remarquable de l'hydrolyse de l'AMPc. Ceci semble induire une interaction entre les voies de signalisation de l’AMPc et du GMPc. Cependant, le rôle de la PDE2 dans le cœur défaillant est très peu connu.Dans ce contexte, nous avons examiné si la PDE2 cardiaque est modifiée dans l’IC chez l’Homme et chez les modèles animaux d’IC, et déterminé le rôle de la PDE2 dans la signalisation β-adrénergique dans les cardiomyocytes. Grâce à l’utilisation de Western blot, de technique radioenzymatique, d’imagerie basée sur le FRET, de la planimétrie, de la microscopie à épifluorescence et des mesures du courant calcique de type L, réalisés sur les tissus myocardiques humains et/ou dans des cardiomyocytes isolés de cœurs des modèles animaux d’IC, respectivement, nous avons montré que l’expression et l’activité de la PDE2 sont augmentées dans les cœurs défaillants. Cette augmentation réduit l’effet d’une stimulation β-adrénergique aiguë, contribuant à la désensibilisation β-adrénergique observée dans l’IC. En accord avec ces résultats, la surexpression de la PDE2 dans des cardiomyocytes sains, réduit l’augmentation des taux d'AMPc et l’amplitude du courant ICa,L et abolit l'effet inotrope positif suite à une stimulation β-adrénergique aiguë, sans affecter la contractilité basale. Plus important, les cardiomyocytes surexprimant la PDE2, montrent une protection contre les réponses hypertrophiques induites par la noradrénaline et contre les arythmies induites par l'isoprotérénol.En conclusion, ce travail met en évidence l'altération de la PDE2 dans l’IC et nous laisse suggérer que l’augmentation de la PDE2 dans l’IC peut constituer un mécanisme de défense important dans des conditions de stress cardiaque, notamment en antagonisant la suractivation de la voie β-adrénergique. Ainsi, l'activation de PDE2 myocardique peut représenter une nouvelle stratégie thérapeutique anti-adrénergique intracellulaire dans l’IC. / Cyclic AMP (cAMP) and cyclic GMP (cGMP) are critical second messengers for the regulation of cardiac function. Their levels are regulated by adenylyl and guanylyl cyclases, respectively, and by cyclic nucleotides phosphodiesterases (PDEs). However, such regulation is altered in heart failure (HF). Indeed diminished cAMP- and augmented cGMP-signaling is characteristic of failing hearts.Among the PDE superfamily, PDE2 has the unique property to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis. This appears to mediate a negative cross-talk between cAMP- and cGMP signaling pathways. However, the role of PDE2 in the failing heart is only poorly understood.In this context, we investigated whether myocardial PDE2 is altered in human and experimental HF and determined PDE2 mediated effects on β-adrenoceptor (β-AR) signaling in cardiomyocytes. Using immunoblotting, radioenzymatic- and FRET-based assays, video-edge-detection, epifluorescent microscopy and L-type Ca2+ current measurements, performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively, we showed that PDE2 is markedly upregulated in failing hearts. This reduces the effect of an acute β-adrenergic stimulation, and contributes to the β-adrenergic desensitization which is a characteristic feature in HF. Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and ICa,L amplitude and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility. Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses and from isoproterenol-induced arrhythmias.In conclusion, this work highlights the alteration of PDE2 in HF and lets us assume that PDE2 upregulation in HF may constitute an important defence mechanism during cardiac stress, e.g. by antagonizing excessive β-AR drive. Thus, activating myocardial PDE2 may represent a novel intracellular anti-adrenergic therapeutic strategy in HF.

<p>Malignant primary brain tumors, gliomas, often overexpress both platelet-derived growth factor (PDGF) ligands and receptors providing an autocrine and/or paracrine boost to tumor growth. Glioblastoma multiforme (GBM) is the most frequent glioma. Its aggressive and infiltrative growth renders it extremely difficult to treat. Median survival after diagnosis is currently only 14 months. </p><p>The present thesis describes the use of retroviral tagging to identify candidate cancer-causing genes that cooperate with PDGF in brain tumor formation. Newborn mice were injected intracerebrally with a Moloney murine leukemia retrovirus carrying the <i>sis</i>/PDGF-B oncogene and a replication competent helper virus. Brain tumors with many characteristics of human glioblastomas developed after 13-42 weeks. </p><p>Analysis of proviral integrations in the brain tumors identified almost 70 common insertion sites (CISs). These CISs were named brain tumor loci and harbored known but also putative novel cancer-causing genes.</p><p>An array with over 15000 unique cDNAs was used to screen for differentially expressed genes in the mouse brain tumors compared to normal brain. Known tumor genes and markers of immature cells were upregulated in the tumors. Short latency tumors were further distinguished as fast growing and GBM-like. Long latency tumors resembled slow-growing oligodendrogliomas and contained significantly less integrations as compared to short latency tumors.</p><p>The gene <i>Prkg2</i>, encoding the cGMP-dependent protein kinase II, was targeted by insertions in two brain tumors. Overexpression of <i>Prkg2</i> in human glioma cell lines led to a reduction in colony formation, cell proliferation and migration. A glioma cell line expressing markers of immature stem cells showed loss of cell adhesion, G1 cell cycle arrest and decreased activation of the survival signaling protein Akt upon stimulation with a cGMP analog that activates the <i>Prkg2</i> protein. The present thesis shows that proviral tagging may be a useful tool in the search for candidate glioma genes.</p>

Thesis (M.Sc. (Pharmacology))--North-West University, Potchefstroom Campus, 2007.

Malignant primary brain tumors, gliomas, often overexpress both platelet-derived growth factor (PDGF) ligands and receptors providing an autocrine and/or paracrine boost to tumor growth. Glioblastoma multiforme (GBM) is the most frequent glioma. Its aggressive and infiltrative growth renders it extremely difficult to treat. Median survival after diagnosis is currently only 14 months. The present thesis describes the use of retroviral tagging to identify candidate cancer-causing genes that cooperate with PDGF in brain tumor formation. Newborn mice were injected intracerebrally with a Moloney murine leukemia retrovirus carrying the sis/PDGF-B oncogene and a replication competent helper virus. Brain tumors with many characteristics of human glioblastomas developed after 13-42 weeks. Analysis of proviral integrations in the brain tumors identified almost 70 common insertion sites (CISs). These CISs were named brain tumor loci and harbored known but also putative novel cancer-causing genes. An array with over 15000 unique cDNAs was used to screen for differentially expressed genes in the mouse brain tumors compared to normal brain. Known tumor genes and markers of immature cells were upregulated in the tumors. Short latency tumors were further distinguished as fast growing and GBM-like. Long latency tumors resembled slow-growing oligodendrogliomas and contained significantly less integrations as compared to short latency tumors. The gene Prkg2, encoding the cGMP-dependent protein kinase II, was targeted by insertions in two brain tumors. Overexpression of Prkg2 in human glioma cell lines led to a reduction in colony formation, cell proliferation and migration. A glioma cell line expressing markers of immature stem cells showed loss of cell adhesion, G1 cell cycle arrest and decreased activation of the survival signaling protein Akt upon stimulation with a cGMP analog that activates the Prkg2 protein. The present thesis shows that proviral tagging may be a useful tool in the search for candidate glioma genes.

Primary cilia are evolutionarily conserved organelles required in a number of signalling pathways influencing the development and behaviour of a diverse range of organisms. More recently, studies into a new class of human diseases known as ciliopathies have helped to shed light on the critical role of this once-ignored signalling centre. Bardet-Biedl syndrome (BBS) proteins localize to the primary cilium and participate in cilium biogenesis and function. BBS is a pleiotropic human disorder with variable severity that is suitable as a disease model for investigating the pathogenesis of a number of common ciliopathy features such as photoreceptor degeneration, renal cysts, and obesity. The C. elegans genome encodes a number of BBS proteins which undergo intraflagellar transport (IFT) at the primary cilium. Given the conservation between C. elegans and human BBS proteins, I hypothesize the existence of unidentified conserved genetic pathways related to the functions of these proteins. Using C. elegans, I characterize novel features of bbs mutants while identifying sources of genomic variation that may elucidate the variability of human BBS features. I show that C. elegans bbs mutants exhibit smaller body size, delayed development, and decreased exploration behaviour. Moreover, I identify a role for the soluble guanylate cyclases GCY-35/GCY-36 in modifying these bbs phenotypes. I conclude that BBS proteins non-cell autonomously influence a set of body cavity neurons in which GCY-35/GCY-36 function genetically upstream of a cGMP-dependent protein kinase (PKG), EGL-4, to control body size. Furthermore, the role of GCY-35/GCY-36 is unique amongst a large number of guanylate cyclases and BBS proteins may influence body size via an IFT-independent function. I explore the biological functions of EGL-4 and conclude that it may regulate body size through multiple cellular mechanisms. I also examine potential candidate genes related to cGMP production and turnover, confirming that additional cGMP-related factors can influence body size although not necessarily in body cavity neurons. In conclusion, I propose a model where BBS-expressing sensory neurons influence body size and development through cGMP-PKG signalling in body cavity neurons while functioning in parallel with additional sensory neurons (possibly BBS-independent) that use similar cGMP-PKG signalling dynamics.

Primary cilia are evolutionarily conserved organelles required in a number of signalling pathways influencing the development and behaviour of a diverse range of organisms. More recently, studies into a new class of human diseases known as ciliopathies have helped to shed light on the critical role of this once-ignored signalling centre. Bardet-Biedl syndrome (BBS) proteins localize to the primary cilium and participate in cilium biogenesis and function. BBS is a pleiotropic human disorder with variable severity that is suitable as a disease model for investigating the pathogenesis of a number of common ciliopathy features such as photoreceptor degeneration, renal cysts, and obesity. The C. elegans genome encodes a number of BBS proteins which undergo intraflagellar transport (IFT) at the primary cilium. Given the conservation between C. elegans and human BBS proteins, I hypothesize the existence of unidentified conserved genetic pathways related to the functions of these proteins. Using C. elegans, I characterize novel features of bbs mutants while identifying sources of genomic variation that may elucidate the variability of human BBS features. I show that C. elegans bbs mutants exhibit smaller body size, delayed development, and decreased exploration behaviour. Moreover, I identify a role for the soluble guanylate cyclases GCY-35/GCY-36 in modifying these bbs phenotypes. I conclude that BBS proteins non-cell autonomously influence a set of body cavity neurons in which GCY-35/GCY-36 function genetically upstream of a cGMP-dependent protein kinase (PKG), EGL-4, to control body size. Furthermore, the role of GCY-35/GCY-36 is unique amongst a large number of guanylate cyclases and BBS proteins may influence body size via an IFT-independent function. I explore the biological functions of EGL-4 and conclude that it may regulate body size through multiple cellular mechanisms. I also examine potential candidate genes related to cGMP production and turnover, confirming that additional cGMP-related factors can influence body size although not necessarily in body cavity neurons. In conclusion, I propose a model where BBS-expressing sensory neurons influence body size and development through cGMP-PKG signalling in body cavity neurons while functioning in parallel with additional sensory neurons (possibly BBS-independent) that use similar cGMP-PKG signalling dynamics.